Drug Trial Radar · NCT06831812
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Jun 12, 2024
Primary completion
Dec 1, 2025
Study completion Dec 1, 2025
Sponsor
- Lead sponsor
- Nuravax, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Arvax
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60. Participants will receive three intramuscular injections of either adjuvanted AV-1959R (100 µg or 300 µg) or adjuvanted placebo at Weeks 0, 4, and 14, followed by an 8-week follow-up. Researchers will monitor for side effects and measure anti-Aβ antibody levels to assess immune response. This study will help determine if AV-1959R is safe and effective in generating a targeted immune response.
Conditions
- Alzheimer Disease
- Alzheimer Disease (AD)
- Alzheimers Disease Prevention
Interventions
AV-1959R (Abeta vaccine)Biological
AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ) to support the primary prevention of Alzheimer's disease and the treatment of asymptomatic preclinical Alzheimer's disease. It is administered intramuscularly (IM) at doses of 100 µg or 300 µg on Weeks 0, 4, and 14, in combination with the adjuvant.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of AV-1959R Compared to PlaceboTime frame: Up to 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arvax
Adelaide, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.